Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


908 Devices inflates IPO to $150m
The chemical analysis device developer has added $20m to an initial public offering following $70m in funding from investors including Utec.
Sonovia sounds out stock market
Bar-Ilan University’s textile developer Sonovia has completed an $18.5m initial public offering on the Tel Aviv Stock Exchange.
WealthNavi navigates its way through $173m IPO
UTokyo Innovation Platform has scored an exit as the online investment platform developer went public on the Tokyo Stock Exchange.
AbCellera amplifies IPO to $556m
The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.
AbCellera accomplishes $483m initial public offering
Shares in the antibody discovery platform developer, advancing UBC research, opened at more than three times their IPO price to net it a valuation topping $15bn.
HeiQ harvests $80.1m from UK listing
ETH Zurich-founded HeiQ chose the London Stock Exchange for its listing having posted a $10.9m operating profit for the first half of the year.
4DMT retries IPO with $75m filing
Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.
Sigilon signals $100m IPO target
Chronic illness drug developer Sigilon Therapeutics, co-founded by MIT and UIC researchers, has filed to go public after raising almost $200m in funding.

Other News

Elliptic Labs detects public listing
The University of Oslo sensor software spinout has started trading on the Merkur Market, part of the Oslo Stock Exchange.
Nanofilm rolls towards stock market
NTU spinout Nanofilm Technologies has seemingly filed a draft prospectus with a view of listing on the domestic Singapore Stock Exchange.
Codiak Biosciences cracks IPO code
Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.
Kronos Bio crushes IPO to raise $250m
MIT's cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.
Galecto elects to target $100m in IPO
Galecto has filed to go public nine years after being founded in Sweden to commercialise research from Lund and Edinburgh universities.
Momentus finds Stable Road to Nasdaq
University of Wyoming-backed Momentus is set to merge with SPAC Stable Road Acquisition in a deal that values the space infrastructure company at $1.2bn.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg